Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation ― Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration ―
Author:
Affiliation:
1. Department of Cardiology, Hokusetsu General Hospital
Publisher
Japanese Circulation Society
Subject
Cardiology and Cardiovascular Medicine,General Medicine
Link
https://www.jstage.jst.go.jp/article/circj/83/5/83_CJ-18-1282/_pdf
Reference27 articles.
1. 1. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safely of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014; 383: 955–962.
2. 2. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: Population based cohort study. BMJ 2015; 350: h1857.
3. 3. Beyer-Westendorf J, Forster K, Ebertz F, Gelbricht V, Schreier T, Gobelt M, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients: Results from Dresden non-interventional oral anticoagulation registry. Europace 2015; 17: 530–538.
4. 4. Lamberts M, Staerk L, Olesen JB, Fosbol EL, Hansen ML, Harboe L, et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: Contemporary findings in real-life Danish patients. J Am Heart Assoc 2017; 6: e004517.
5. 5. Steinberg BA, Shrader PS, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Off-label dosing of non-vitamin K anticoagulants and adverse outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol 2016; 68: 2597–2604.
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Letter by Suwa et al Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”;Circulation;2024-07-09
2. Clinical characteristics of apixaban prescription in AF patients with single dose-reduction criterion: the ASPIRE (efficAcy and safety of aPixaban in rEal-world practice in Korean frail patients with atrial fibrillation) study;Frontiers in Cardiovascular Medicine;2024-06-10
3. The potential use of laboratory monitoring during individualizing the dosage of direct oral anticoagulants - a literature review;Vnitřní lékařství;2023-10-26
4. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study;Clinical and Translational Medicine;2023-05
5. Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing;Circulation Reports;2023-03-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3